EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Ovitrelle

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
N/0087	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/11/2022		PL	
IA/0086	B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits	04/07/2022	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

IB/0085	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	10/02/2022	n/a		
IB/0084	B.IV.1.z - Change of a measuring or administration device - Other variation	18/10/2021	14/10/2022	SmPC, Labelling and PL	Update of the product information related to the introduction of a second injection needle in each box of Ovitrelle 250 mcg solution for injection in pre-filled pen (EU/1/00/165/008).
IA/0083/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	03/08/2021	n/a		
II/0081	Changes in sections 4.1, 4.2, 4.4 and 4.6 of the SmPC in order to update the terminology, in 4.3 to amend existing contraindications and in 4.8 to delete certain adverse drug reactions (ADRs) and add gastrointestinal ADRs with frequency common, with the aim to align the Product Information with similar	15/10/2020	11/10/2021	SmPC, Labelling and PL	

	text provided for other gonadotropin products. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1 and performed minor linguistic changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IA/0082	A.7 - Administrative change - Deletion of manufacturing sites	02/09/2020	n/a		
PSUSA/736/201909	Periodic Safety Update EU Single assessment - choriogonadotropin alfa	17/04/2020	n/a		PRAC Recommendation - maintenance
IB/0079	B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer	20/01/2020	n/a		
II/0078	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	06/06/2019	n/a		
N/0077	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	29/11/2018	23/08/2019	Labelling and PL	

IA/0076	B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits	26/11/2018	n/a		
T/0075	Transfer of Marketing Authorisation	03/09/2018	20/09/2018	SmPC, Labelling and PL	
II/0073/G	This was an application for a group of variations. Update of section 4.8 of the SmPC in order to indicate that thromboembolism can also occur without the presence of ovarian hyperstimulation syndrome (OHSS). The package leaflet and risk management plan (RMP) version 6.0 are updated accordingly. The RMP is also updated to extend the important potential risk of 'misuse' to 'weight loss and anabolic growth promoting effect'. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet, to make editorial changes in the product information and in the Annex A (list of authorised presentations). The MAH also took the opportunity to make some revisions in the RMP. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated	06/09/2018	23/08/2019	SmPC and PL	Thromboembolism both in association with and separate from ovarian hyperstimulation syndrome (OHSS) has been reported in post-marketing. The frequency of the occurrence of thromboembolism remains very rare. Misuse including weight loss and anabolic growth promoting effect is an important potential risk listed in the risk management plan.

	by new additional data to be submitted by the MAH where significant assessment is required				
IA/0074/G	This was an application for a group of variations. B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure	17/08/2018	n/a		
IB/0072/G	This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)	30/08/2017	n/a		
IB/0071	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process	02/06/2017	n/a		

	of the AS				
PSUSA/736/201609	Periodic Safety Update EU Single assessment - choriogonadotropin alfa	05/05/2017	n/a		PRAC Recommendation - maintenance
IB/0070	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	22/03/2017	n/a		
IA/0069/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	17/02/2017	n/a		
IB/0066	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	04/12/2016	10/11/2017	Annex II, Labelling and PL	
IB/0067	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	22/11/2016	n/a		
IA/0065	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	22/07/2015	n/a		

IG/0500	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	17/11/2014	n/a		
IB/0063	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	25/09/2014	n/a		
IA/0061/G	This was an application for a group of variations. B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a	29/07/2014	n/a		

	national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
IG/0461	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	22/07/2014	n/a		

PSUV/0059	Periodic Safety Update	08/05/2014	n/a		PRAC Recommendation - maintenance
IB/0060	Update of the Product Information to comply with QRD template version 9. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/04/2014	13/05/2015	SmPC, Annex II, Labelling and PL	
N/0055	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/11/2013	17/12/2013	PL	
IB/0057	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	29/10/2013	n/a		
IA/0058/G	This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation	21/10/2013	n/a		
IB/0056	B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	16/10/2013	n/a		

IB/0052	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	30/08/2013	n/a		
IA/0054/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	19/08/2013	n/a		
IA/0053	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	28/06/2013	n/a		
WS/0380	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Change to the control of the active substance B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits	30/05/2013	n/a		

IB/0050	C.I.7.a - Deletion of - a pharmaceutical form	14/12/2012	17/12/2013	SmPC, Annex II, Labelling and PL	
IA/0049	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	12/11/2012	n/a		
IG/0224	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	11/10/2012	n/a		
IB/0041	C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH	21/10/2011	n/a	SmPC and PL	
WS/0148	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. New TSE certificate for a raw material used in the manufacture of the active substance. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer	21/07/2011	21/07/2011		
IG/0087	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph	18/07/2011	n/a		

	of the Ph. Eur. or national pharmacopoeia of a Member State				
IG/0076/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	01/07/2011	n/a		
X/0040	To register an additional pharmaceutical form: solution for injection in pre-filled pen (250 micrograms/0.5 ml) Annex I_2.(d) Change or addition of a new pharmaceutical form	14/04/2011	23/06/2011	SmPC, Labelling and PL	The MAH registered a new pharmaceutical form: solution for injection in a cartridge pre-installed in a disposable pen. No changes have been made to the currently approved strength (250 micrograms), drug substance, drug product formulation, indication, posology and route of administration.
IG/0069	A.7 - Administrative change - Deletion of manufacturing sites	12/05/2011	n/a		
N/0039	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/01/2010	n/a	PL	
IB/0038	IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening	23/10/2009	n/a		

IA/0037	IA_01_Change in the name and/or address of the marketing authorisation holder	09/07/2009	n/a	SmPC, Labelling and PL	
IA/0036	IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product	31/03/2009	n/a	Annex II and PL	
IA/0035	IA_05_Change in the name and/or address of a manufacturer of the finished product	07/11/2008	n/a	Annex II and PL	
IB/0034	IB_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits	06/11/2008	n/a		
II/0032	Change(s) to the manufacturing process for the active substance	30/05/2008	05/06/2008		
II/0031	Quality changes	24/04/2008	06/05/2008		
IA/0033	IA_05_Change in the name and/or address of a manufacturer of the finished product	12/02/2008	n/a		
II/0028	Change(s) to the test method(s) and/or specifications for the active substance	24/01/2008	28/01/2008		
IB/0029	IB_36_a_Change in shape or dimensions of the container/closure - sterile ph. forms/biologicals	09/10/2007	n/a		
IA/0030	IA_28_Change in any part of primary packaging material not in contact with finished product	01/10/2007	n/a		

II/0027	Change(s) to the manufacturing process for the finished product	19/07/2007	08/08/2007		
II/0024	Change(s) to the manufacturing process for the finished product	19/07/2007	08/08/2007		
N/0026	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/06/2007	n/a	PL	
IB/0025	IB_37_a_Change in the specification of the finished product - tightening of specification limits	15/03/2007	n/a		
II/0023	Change(s) to the manufacturing process for the active substance	16/11/2006	20/11/2006		
N/0022	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/08/2006	n/a	Labelling	
R/0020	Renewal of the marketing authorisation.	15/09/2005	31/01/2006	SmPC, Annex II, Labelling and PL	Based on the CHMP review of the available information, the CHMP considered that the quality, the efficacy and the safety of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered by consensus that the benefit/risk profile of Ovitrelle in the approved therapeutic indication remains favourable. The Committee for Medicinal Products for Human Use recommended therefore the renewal of the Marketing Authorisation for Ovitrelle. The CHMP was of the opinion that no additional 5-year renewal is required. The renewal required amendments to the terms of the

					Community Marketing Authorisation. The following annexes have been amended: I, II, IIIA and IIIB. Future PSURs submission will take place in accordance to Article 24(3) of Regulation EC 726/2004.
II/0021	Update of Summary of Product Characteristics, Labelling and Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet	15/09/2005	25/10/2005	SmPC, Annex II, Labelling and PL	The MAH applied to update the SPC further to the Assessment Report of PSUR 6 of Ovitrelle to reflect the Core Safety Information with regards to complications of Ovarian Hyperstimulation syndrome and to include allergic reactions presenting as a rash in the 4.8 section as very rare possible side effects. As a consequence, the PL was also updated.
II/0019	Change(s) to the test method(s) and/or specifications for the active substance	15/09/2005	05/10/2005		
IA/0018	IA_16_b_Submission of new TSE certificate relating to active substance - other substances	24/01/2005	n/a		
N/0016	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/11/2004	n/a	PL	
IA/0017	IA_05_Change in the name and/or address of a manufacturer of the finished product	06/10/2004	n/a		
N/0015	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	27/07/2004	n/a	PL	
IB/0014	IB_42_a_01_Change in shelf-life of finished product - as packaged for sale	10/03/2004	n/a	SmPC	
IA/0013	IA_06_a_Change in ATC code: Medicinal products for	27/11/2003	n/a	SmPC	

	human use				
X/0007	X-3-iv_Change or addition of a new pharmaceutical form	24/07/2003	24/10/2003	SmPC, Annex II, Labelling and PL	
I/0011	31_Change in container shape	08/10/2003	23/10/2003		
I/0010	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	08/10/2003	23/10/2003		
II/0012	Change(s) to the test method(s) and/or specifications for the active substance	25/09/2003	02/10/2003		
N/0009	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/02/2003	17/03/2003	PL	
I/0008	15a_Change in IPCs applied during the manufacture of the product	16/01/2003	22/01/2003		
I/0004	01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process	13/09/2002	27/09/2002		
I/0005	01_Change in the name of a manufacturer of the medicinal product	21/08/2002	10/09/2002		
I/0006	11b_Change in supplier of an intermediate compound used in manufacture of the active substance	21/08/2002	n/a		
I/0003	12a_Change in specification of starting material/intermediate used in manuf. of the active	22/03/2002	10/04/2002		

	substance				
I/0002	03_Change in the name and/or address of the marketing authorisation holder	20/07/2001	10/09/2001	SmPC, Labelling and PL	
I/0001	02_Change in the name of the medicinal product (either invented name of common name)	20/07/2001	10/09/2001	SmPC, Labelling and PL	